Skip to main content
Nykode Therapeutics ASA logo

Nykode Therapeutics ASA — Investor Relations & Filings

Ticker · NYKD ISIN · NO0010714785 LEI · 254900UKQHWYZJD22017 OL Manufacturing
Open in API
Filings indexed 493 across all filing types
Latest filing 2025-05-23 Investor Presentation
Country NO Norway
Listing OL NYKD

About Nykode Therapeutics ASA

https://nykode.com/

Nykode Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company's core is its proprietary Vaccibody™ technology, a modular platform designed to create targeted vaccines. This technology works by linking antigens to a targeting unit, which delivers them directly to antigen-presenting cells. This mechanism is engineered to induce rapid, potent, and long-lasting T-cell and antibody immune responses. Nykode's development pipeline is focused on generating therapeutics for a range of diseases, with a primary emphasis on oncology and infectious diseases.

Recent filings

Filing Released Lang Actions
Nykode Therapeutics Highlights New Data in Two Poster Presentations at the 2025 ASCO Annual Meeting
Investor Presentation Classification · 99% confidence The document is titled "Company Announcement" and details the presentation of new clinical data (VB10.16 and VB10.NEO) at the 2025 ASCO Annual Meeting via two poster presentations. It provides abstract numbers, session details, and key findings from these presentations. This content is typical of an announcement made by a company to inform investors and the public about scientific data being shared at a major conference. It is not a full Annual Report (10-K), an Interim Report (IR), or a formal Earnings Release (ER). Since it is an announcement about scientific data being presented, it fits best under Investor Presentation (IP) if it were the presentation itself, but as an announcement *about* presentations, it is a general corporate communication. Given the options, this type of scientific update announcement, which is highly relevant to investors but not a formal financial filing, often falls under Investor Presentation (IP) if it contains substantial scientific/strategy detail, or sometimes Regulatory Filings (RNS) if it's a broad disclosure. However, since it is specifically detailing scientific findings intended for investors and analysts, and it is not a transcript (CT) or a formal financial report, 'Investor Presentation' (IP) is the most appropriate category for the *content* being highlighted, even though this specific document is the *announcement* of the presentation. Given the detailed scientific nature of the content being highlighted (Abstracts, clinical outcomes), IP is a strong fit, representing the type of information being disseminated to the investment community regarding R&D progress. If the document were merely stating 'We will present posters,' RPA might apply, but since it includes the core data highlights, IP is better.
2025-05-23 English
Nykode Therapeutics Highlights New Data in Two Poster Presentations at the 2025 ASCO Annual Meeting
Regulatory Filings Classification · 99% confidence The document is an announcement by Nykode Therapeutics detailing the presentation of new clinical trial data (VB10.16 and VB10.NEO) via poster presentations at the 2025 ASCO Annual Meeting. It summarizes key findings, abstract numbers, session details, and provides links where the actual presentations will be made available later. This content is characteristic of an Investor Presentation (IP) or a detailed scientific update, rather than a formal regulatory filing like a 10-K, an Earnings Release (ER), or a simple Report Publication Announcement (RPA) which usually just states a report is available. Since it provides detailed scientific and clinical data summaries intended for investors and analysts, 'Investor Presentation' (IP) is the most fitting category, even though the data is presented in poster format at a conference.
2025-05-23 English
Nykode Therapeutics ASA - Notice of Annual General Meeting
AGM Information Classification · 100% confidence The document is explicitly titled "INNKALLING TIL ORDINÆR GENERALFORSAMLING I NYKODE THERAPEUTICS ASA" (NOTICE OF ANNUAL GENERAL MEETING IN NYKODE THERAPEUTICS ASA). The agenda items cover standard AGM topics such as approval of the annual report, remuneration guidelines, election of the board, dividend distribution, and authorization to issue shares. This content directly corresponds to the purpose of an Annual General Meeting (AGM) notice/materials.
2025-05-05 Norwegian
Nykode Therapeutics ASA - Notice of Annual General Meeting
AGM Information Classification · 98% confidence The document explicitly states it is a 'Notice of Annual General Meeting' and provides the date, time, and location for the meeting. This directly corresponds to the definition of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting. Although it is a 'Notice', the content is central to the AGM event itself, making AGM-R the most specific fit over a general RPA or RNS.
2025-05-05 English
Nykode Therapeutics - Annual Report 2024
Annual Report (ESEF) Classification · 100% confidence FY 2024
2025-04-29 English
Nykode Therapeutics - Annual Report 2024
Annual Report Classification · 100% confidence The document is a comprehensive annual report for Nykode Therapeutics ASA for the fiscal year ended December 31, 2024. It includes a Board of Directors report, detailed financial statements (income statement, balance sheet, cash flows), notes to the financial statements, and an independent auditor's report. It is clearly the full annual report rather than an announcement or a summary. FY 2024
2025-04-29 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.